[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cytek Biosciences Inc (CTKB)

Cytek Biosciences Inc (CTKB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Cytek Biosciences Q1 Earnings Call Highlights

Cytek Biosciences (NASDAQ:CTKB) reported first-quarter 2026 revenue of $44.1 million, up 6% from $41.5 million in the year-ago quarter, as strength in the U.S. and continued growth in recurring revenue...

CTKB : 4.61 (-6.30%)
Cytek Biosciences Reports First Quarter 2026 Financial Results

FREMONT, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial...

CTKB : 4.61 (-6.30%)
Cytek Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026

FREMONT, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced that it will report financial results for the first...

CTKB : 4.61 (-6.30%)
Cytek® Biosciences Celebrates One Year of Operations at Singapore Facility, Accelerating Growth and Regional Impact

FREMONT, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- One year after opening its 8,500-square-foot Singapore facility, spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq: CTKB) is marking...

CTKB : 4.61 (-6.30%)
Cytek Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results  and Provides 2026 Outlook 

FREMONT, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Cytek ®  Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial...

CTKB : 4.61 (-6.30%)
Cytek Biosciences to participate at the TD Cowen 46th Annual Health Care Conference

FREMONT, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming...

CTKB : 4.61 (-6.30%)
Cytek Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

FREMONT, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the fourth quarter...

CTKB : 4.61 (-6.30%)
Cytek Biosciences Announces Preliminary Fourth Quarter and Full Year 2025 Revenue Results

FREMONT, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced preliminary, unaudited revenue results for the fourth...

CTKB : 4.61 (-6.30%)
TIME Recognizes Cytek® Biosciences as One of America’s Growth Leaders of 2026

FREMONT, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Spectral flow cytometry leader  Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced its inclusion on TIME’s 2026 list of America’s Growth Leaders....

CTKB : 4.61 (-6.30%)
Cytek® Muse® Micro Cell Analyzer Wins BioTech Breakthrough Award for Drug Discovery Solution of the Year

FREMONT, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB) announced today that its Cytek ® Muse ® Micro cell analyzer has been named Drug Discovery Solution...

CTKB : 4.61 (-6.30%)

Barchart Exclusives

Palantir Stock Has a ‘High-Class Problem’: Demand for Its Software Is Far Outpacing Supply
Palantir’s greatest challenge may no longer be demand, but how quickly it can deliver AI software to customers. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.